Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.11.18 (
MAP
)
7,412
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
ERK7
is a unique member of the extracellular signal-regulated kinase (ERK) subfamily of
MAP
kinases. Although
ERK7
shares a TEY motif in the activation loop of the kinase, it displays constitutive activation, nuclear localization, and growth inhibitory properties that are regulated by its C-terminal domain. Because
ERK7
is expressed at low levels compared with ERK2 and its activity is dependent upon its expression level, we investigated the mechanism by which
ERK7
expression is regulated. We now show that
ERK7
expression is regulated by ubiquitination and rapid proteosomal turnover. Furthermore, both the kinase domain and the C-terminal tail are independently degraded at a rate comparable with that of the intact protein. Analysis of a series of chimeras between ERK2 and
ERK7
reveal that the N-terminal 20 amino acids of the kinase domain are a primary determinant of
ERK7
degradation. Fusion of the N-terminal 20 amino acids is both necessary and sufficient to cause proteolytic degradation of both ERK2 and green fluorescent protein. Finally,
ERK7
is stabilized by an N-terminal mutant of Cullin-1 suggesting that
ERK7
is ubiquitinated by the Skip1-Cullin-F box complex. These results indicate that
ERK7
is a highly regulated enzyme whose cellular expression and kinase activation level is tightly controlled by the ubiquitin-proteosome pathway.
...
PMID:ERK7 expression and kinase activity is regulated by the ubiquitin-proteosome pathway. 1503 83